Clarus Wealth Advisors Has $783,000 Position in Stryker Co. (NYSE:SYK)

Share on StockTwits

Clarus Wealth Advisors grew its holdings in shares of Stryker Co. (NYSE:SYK) by 71.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,620 shares of the medical technology company’s stock after acquiring an additional 1,509 shares during the period. Clarus Wealth Advisors’ holdings in Stryker were worth $783,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. D.B. Root & Company LLC grew its stake in shares of Stryker by 3.0% in the 2nd quarter. D.B. Root & Company LLC now owns 1,724 shares of the medical technology company’s stock valued at $354,000 after buying an additional 50 shares during the period. Cetera Advisor Networks LLC lifted its position in Stryker by 1.3% in the 2nd quarter. Cetera Advisor Networks LLC now owns 4,447 shares of the medical technology company’s stock valued at $911,000 after acquiring an additional 56 shares in the last quarter. Bailard Inc. lifted its position in Stryker by 0.6% in the 2nd quarter. Bailard Inc. now owns 9,219 shares of the medical technology company’s stock valued at $1,895,000 after acquiring an additional 57 shares in the last quarter. Pinnacle Bank lifted its position in Stryker by 7.5% in the 2nd quarter. Pinnacle Bank now owns 855 shares of the medical technology company’s stock valued at $176,000 after acquiring an additional 60 shares in the last quarter. Finally, CFO4Life Group LLC lifted its position in Stryker by 2.3% in the 2nd quarter. CFO4Life Group LLC now owns 2,719 shares of the medical technology company’s stock valued at $559,000 after acquiring an additional 60 shares in the last quarter. Hedge funds and other institutional investors own 72.95% of the company’s stock.

Shares of Stryker stock traded up $2.85 during mid-day trading on Friday, hitting $214.14. 34,539 shares of the stock were exchanged, compared to its average volume of 1,121,147. Stryker Co. has a 12 month low of $144.75 and a 12 month high of $223.45. The company has a 50-day simple moving average of $217.04 and a 200 day simple moving average of $202.89. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.26 and a current ratio of 2.07. The company has a market capitalization of $77.77 billion, a P/E ratio of 29.27, a P/E/G ratio of 2.52 and a beta of 0.81.

Stryker (NYSE:SYK) last posted its earnings results on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.93 by $0.05. Stryker had a net margin of 24.99% and a return on equity of 25.98%. The firm had revenue of $3.65 billion for the quarter, compared to analysts’ expectations of $3.60 billion. During the same quarter last year, the firm earned $1.76 EPS. The company’s quarterly revenue was up 9.9% compared to the same quarter last year. Analysts predict that Stryker Co. will post 8.21 EPS for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 31st. Shareholders of record on Monday, September 30th will be given a dividend of $0.52 per share. The ex-dividend date is Friday, September 27th. This represents a $2.08 annualized dividend and a dividend yield of 0.97%. Stryker’s dividend payout ratio is currently 28.45%.

In other news, VP M Kathryn Fink sold 28,690 shares of the firm’s stock in a transaction that occurred on Thursday, September 19th. The shares were sold at an average price of $220.97, for a total transaction of $6,339,629.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Timothy J. Scannell sold 4,666 shares of the firm’s stock in a transaction that occurred on Tuesday, July 16th. The stock was sold at an average price of $205.88, for a total transaction of $960,636.08. Following the sale, the insider now owns 155,963 shares of the company’s stock, valued at approximately $32,109,662.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 51,637 shares of company stock worth $11,240,206. Insiders own 7.20% of the company’s stock.

Several equities analysts recently weighed in on SYK shares. Cantor Fitzgerald raised their price target on shares of Stryker from $190.00 to $230.00 and gave the company a “neutral” rating in a research report on Friday, July 26th. Raymond James set a $240.00 price target on shares of Stryker and gave the company a “buy” rating in a research report on Friday, July 26th. Canaccord Genuity raised their price target on shares of Stryker from $195.00 to $233.00 and gave the company a “buy” rating in a research report on Friday, July 26th. Svb Leerink reaffirmed an “outperform” rating on shares of Stryker in a research report on Wednesday, July 10th. Finally, BTIG Research set a $228.00 price target on shares of Stryker and gave the company a “buy” rating in a research report on Thursday, September 5th. Six analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $214.89.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.

Further Reading: What is the strike price in options trading?

Institutional Ownership by Quarter for Stryker (NYSE:SYK)

Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.